Von Willebrand Factor and ADAMTS13

Study shows pomalidomide prolongs survival in refractory myeloma patients

Use of Daratumumab, a CD38 monoclonal antibody, in advanced multiple myeloma

Targeting JAK-STAT pathway in malignant and non-malignant cells in myeloproliferative neoplasms

Addition of obinutuzumab or rituximab to chlorambucil for chronic lymphocytic leukaemia

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma

Vemurafenib and ipilimumab for metastatic melanoma

Science behind phase I clinical trials: targeting tumour cell development pathways

Next generation of anti-cancer agents: data from ASCO 2013

Phase I study measures effect of ipilimumab and nivolumab combination in melanoma patients

Axillary radiotherapy provides alternative to invasive early stage breast cancer surgery

Comment on progression free survival in lung cancer patients and the GALAXY-1 trial